Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05298423 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 611
- Enrollment target
- 20
- Study locations
NCT05298423: Active Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Merck Sharp & Dohme.
NCT05298423 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 611 participants, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05298423, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 611 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG pemetrexed
- DRUG etoposide
- BIOLOGICAL durvalumab
- BIOLOGICAL pembrolizumab/vibostolimab
Study Locations (20)
Florida
- Millennium Oncology Research Clinic ( Site 2801) - Hollywood
- Mid Florida Hematology and Oncology Center ( Site 2800) - Orange City
- Moffitt Cancer Center ( Site 2818) - Tampa
California
- VA Long Beach Healthcare System ( Site 2831) - Long Beach
- VA West Los Angeles Medical Center ( Site 2808) - Los Angeles
Massachusetts
- Boston Medical Center ( Site 2829) - Boston
- University of Massachusetts Chan Medical School ( Site 2815) - Worcester
Missouri
- University of Missouri Hospital ( Site 2839) - Columbia
- Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837) - Springfield
New York
- Icahn School of Medicine at Mount Sinai ( Site 2821) - New York
- White Plains Hospital ( Site 2835) - White Plains
Pennsylvania
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827) - Lancaster
- Thomas Jefferson University - Clinical Research Institute ( Site 2813) - Philadelphia
Texas
- Millennium Research & Clinical Development ( Site 2811) - Houston
- Central Texas Veterans health care-Oncology & Hematology ( Site 2819) - Temple
Illinois
- University of Chicago Medical Center ( Site 2828) - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2026-08-19 |
| Phase | Phase 3 |
What the registry record for NCT05298423 still lists
NCT05298423 is an interventional study that assigns participants to a tested intervention. The registered 611 participants enrollment target is mid-sized for trials with a published cap, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (92% higher).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT05298423 names 20 study sites across 12 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05298423 about?
NCT05298423 is a clinical study titled "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)". Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall th...
What is the current status of trial NCT05298423?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 611 participants. The study started on 2022-05-03. Estimated completion is 2026-08-19.
What conditions does trial NCT05298423 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT05298423?
The interventions under investigation include: cisplatin (DRUG), pemetrexed (DRUG), etoposide (DRUG), durvalumab (BIOLOGICAL), pembrolizumab/vibostolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05298423?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05298423 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05298423's enrollment target sits among peer trials
611 24th of 130 higher than 107 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT04590326 · 612 participants · Phase 1
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- NCT06266416 · 612 participants · NA
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI